Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. (KDNY) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
kdny · stock forecast · 11 analysts (3M) · FMP · updated Mar 26, 2024
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Hold
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$30.00
Consensus
$30.00
-25.7% upside
Low
$30.00
Median: $30 · Last Close: $40.39
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · KDNY · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-08-08 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-08-07 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-08-01 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2023-07-31 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2023-06-21 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-06-20 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-06-14 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
| 2023-06-13 | SVB Leerink | Downgrade ↓ | Outperform→Perform |
| 2023-06-13 | Stifel | Downgrade ↓ | Buy→Hold |
| 2023-06-13 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
Wall Street analysts have recently issued updated ratings on Chinook Therapeutics, Inc. (KDNY) stock. Of the recent 46 rating actions, 1 were upgrades and 18 were downgrades. 11 analysts currently cover KDNY.
Analyst Recommendation Trends
KDNY analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast KDNY EPS of $— for the current fiscal year, based on estimates from 0 analysts. The KDNY revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The KDNY stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KDNY price target is $30.00 (-25.7% upside), with an analyst consensus of Hold.
Chinook Therapeutics, Inc. trades on NASDAQ under the ticker KDNY. The KDNY stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 18% of covering analysts.
Frequently asked questions
KDNY forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month KDNY price target is $30.00, with a high forecast of $30.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies -25.7% potential upside from the current price of $40.39.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.